Human Induced Pluripotent Stem Cell-Based Cardiac Tissue Engineering for Myocardial Infarction.

Objective: To outline progress in induced pluripotent stem cells (iPSCs) in generating iPSC-derived cardiovascular cell lineages, and cardiac tissue engineering. Materials and methods: A data search for original articles was conducted on PubMed, using keywords: "induced pluripotent stem cells" OR "iPSCs" AND "myocardial infarction" OR "heart failure" AND "cardiomyocyte" on December 18, 2021. Search results were filtered and selected by titles and abstract to get relevant articles, which contained data on iPSC-related tissue engineering for heart tissue repair after myocardial infarction. Data were grouped and synthesize as text. Results and Discussion: we got 35 articles that provide information on cell based therapy, iPSCs, advancement in creating efficient techniques for generating iPSC-derived cardiovascular cell lineages, and recent cardiac tissue engineering advances in myocardial infarction animal models. iPSCs can be derived from skin fibroblasts by expressing four transcription factors that were found to be critical for cellular reprogramming into inner cell mass derived ESC-like cells, namely Oct3/4, c-Myc, Sox2 and Klf4. Cardiomyocytes can be produced from iPSC using special medium and supplements. Tissue engineering can be made possible by 3D printing technique and showed promising results upon transplantation. Conclusion: Tissue engineering using patient-derived human iPSC-cardiomyocytes holds great potential in medicine because it might avoid the problem of possible immune rejection. [ABSTRACT FROM AUTHOR]